Aniracetam

Aniracetam

Aniracetam is a synthetic racetam derivative originally developed in the 1970s and heavily documented across neurochemical, cognitive, and synaptic transmission research models. Structurally related to piracetam, Aniracetam is distinguished by its significantly higher lipophilicity, which directly influences its molecular distribution properties and cell membrane permeability in laboratory environments. It serves as a fundamental benchmark compound in comparative pharmacology and structure-activity relationship (SAR) studies targeting central nervous system mechanics.

Technical Specifications

Mechanism of Action & Core Research Interests

In vitro and in vivo laboratory designs focus heavily on Aniracetam due to its role as a positive allosteric modulator of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors. Because it functions as an ampakine-like agent rather than a direct receptor agonist, it changes receptor kinetics without direct activation.

Scientists utilize this mechanism to evaluate:

• Synaptic Efficiency: Observing alterations in baseline synaptic responsiveness and signal transmission integrity between neurons.

• Long-Term Potentiation (LTP): Investigating cellular mechanisms underlying synaptic plasticity, learning pathways, and memory formation models.

• Secondary Neuromodulation: Evaluating indirect downstream influences on dopaminergic and serotonergic signaling pathways.

• Class Comparisons: Testing alongside related molecules like oxiracetam and pramiracetam to map out structural tolerance profiles across the broader racetam family.

Storage & Laboratory Preservation

To ensure experimental reproducibility and safeguard the compound against premature degradation, adhere to strict laboratory preservation steps:

• Environmental Control: Store in a cool, dry environment completely isolated from ambient heat, moisture, and high-humidity levels.

• Light Mitigation: Keep the compound shielded from direct light and UV exposure to protect structural integrity.

• Container Integrity: Maintain an airtight seal on the primary containment unit immediately following analytical sampling.

Research Use Only Disclaimer: This product is developed, manufactured, and distributed strictly as a Research Use Only (RUO) chemical compound intended exclusively for in vitro laboratory assays and academic investigation. It is not a dietary supplement, medication, or consumer drug product, and it is strictly unapproved for human or veterinary consumption. Kimera Chems explicitly prohibits its use for therapeutic, clinical, or diagnostic applications.

Frequently Asked Questions

Why is Aniracetam classified as an ampakine-like compound in research?

Aniracetam is categorized this way because it acts as a positive allosteric modulator of AMPA-type glutamate receptors. It slows down receptor desensitization and deactivation rather than directly binding as a baseline agonist.

How does Aniracetam’s solubility affect its laboratory preparation?

Aniracetam is highly lipophilic (fat-soluble) and exhibits very poor solubility in plain water. For accurate laboratory assay preparation, it must be dissolved into compatible organic solvents like dimethyl sulfoxide (DMSO) or ethanol before being introduced to experimental buffers.

Is this compound identical to Piracetam?

No. While it shares a foundational chemical lineage, Aniracetam features an anisoyl modification at the pyrrolidinone core. This structural adjustment dramatically increases its lipophilicity and modifies its receptor binding affinity compared to first-generation racetams.